PRGO
HealthcarePerrigo Company plc · Drug Manufacturers - Specialty & Generic · $2B
What is Perrigo Company plc?
Perrigo Company plc is a global provider of over-the-counter health and wellness products, helping consumers manage everyday health conditions without a prescription. Headquartered in Dublin, Ireland, Perrigo serves markets across North America and Europe through retail and pharmacy channels.
Perrigo operates through two segments: Consumer Self-Care Americas and Consumer Self-Care International. The Americas segment develops and sells store-brand OTC products across categories such as upper respiratory, pain relief, digestive health, nutrition, skincare, and oral care in the US, Canada, Mexico, and South America. The International segment distributes consumer self-care brands through pharmacies, wholesalers, and grocery retailers across roughly 23 countries, primarily in Europe. Perrigo also provides contract manufacturing services to third parties.
Perrigo was founded in 1887 and is headquartered in Dublin, Ireland.
- Store-brand OTC health and wellness products
- Upper respiratory, pain, and sleep-aid solutions
- Digestive health and nutrition supplements
- Skincare and personal hygiene products under owned brands
- Contract manufacturing services for consumer healthcare
Is PRGO a Good Stock to Buy?
UQS Score rates PRGO as Below Average overall.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the business carries a more manageable risk profile than its overall score might imply. Valuation is rated Attractive, meaning the stock may be priced at a discount relative to its fundamentals, which could interest value-oriented investors.
Quality, Moat, and Growth are all rated Weak, pointing to meaningful challenges in competitive positioning, earnings quality, and the company's ability to expand at a compelling pace.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PRGO pay dividends?
Yes — Perrigo Company plc pays a dividend.
Perrigo pays a regular dividend, which may appeal to income-focused investors seeking exposure to the consumer healthcare space. Given the company's Weak Quality and Growth ratings, investors should weigh the sustainability of the dividend against the underlying business fundamentals. The Attractive Valuation rating adds context for those evaluating total return potential alongside income.
When does PRGO report earnings?
Perrigo reports earnings on a quarterly cadence, typical for US-listed equities.
The company's Weak Quality and Growth pillar ratings suggest recent results have faced headwinds in profitability and top-line expansion. The relatively Good Risk rating indicates the balance sheet and operational structure have provided some stability amid those pressures.
For the most recent quarter's results and guidance, visit Perrigo's official investor relations page.
PRGO Price History
-69.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
PRGO Long-term Outlook
Perrigo's fundamental outlook reflects the tension between an Attractive Valuation and Weak scores across Quality, Moat, and Growth. The business operates in a competitive OTC healthcare market where store-brand pricing pressure and category maturity can limit upside. The Good Risk rating suggests the company is not in acute financial distress, but meaningful re-rating likely depends on demonstrable improvement in margins and organic growth.
Growth drivers
- Expansion of store-brand OTC products in underpenetrated international markets
- Potential margin recovery through operational restructuring and cost discipline
- Consumer shift toward affordable self-care alternatives to branded pharmaceuticals
Key risks
- Sustained weakness in core business quality and competitive positioning
- Pricing pressure from retailers and branded OTC competitors
- Execution risk in international segment amid currency and regulatory complexity
PRGO vs Peers
Perrigo competes in the broader healthcare and consumer self-care space alongside companies of varying scale and focus.
Harrow focuses on ophthalmology and specialty pharmaceutical products, operating in a more niche segment than Perrigo's broad OTC consumer portfolio.
ANI Pharmaceuticals concentrates on generic and branded prescription drugs, giving it a different regulatory and margin profile compared to Perrigo's OTC-first model.
Cronos operates in the cannabis sector, making it a distinct alternative for investors seeking consumer wellness exposure outside traditional OTC healthcare.
Frequently Asked Questions
What does Perrigo Company do?
Perrigo develops, manufactures, and sells over-the-counter health and wellness products under store-brand and owned brand names. It operates across North America and roughly 23 countries in Europe, serving categories like upper respiratory, pain relief, digestive health, skincare, and oral care. The company also provides contract manufacturing services.
Does PRGO pay dividends?
Yes, Perrigo pays a regular dividend. Income-focused investors should review the current dividend rate and payout history on Perrigo's investor relations page, and consider the company's Weak Quality and Growth ratings when assessing long-term dividend sustainability.
When does PRGO report earnings?
Perrigo reports earnings on a quarterly cadence, consistent with standard practice for US-listed companies. For the exact schedule and most recent results, check Perrigo's investor relations page directly.
Is PRGO a good stock to buy?
UQS Score rates PRGO as Below Average, reflecting Weak scores in Quality, Moat, and Growth. However, the Valuation pillar is rated Attractive and Risk is rated Good, which may interest investors with a contrarian or value-oriented approach. The complete pillar breakdown is available to Pro members.
Is PRGO overvalued?
Based on the UQS Valuation pillar, PRGO is rated Attractive — suggesting the stock may be trading at a discount relative to its fundamentals. That said, a low valuation alone does not offset the Weak ratings in Quality, Moat, and Growth. Full valuation metrics are available in the Pro analysis.
How does PRGO compare to its competitors?
Perrigo's OTC consumer healthcare model differs meaningfully from peers like Harrow Health, which focuses on ophthalmology, and ANI Pharmaceuticals, which centers on prescription generics. Cronos Group operates in cannabis wellness, a distinct category. Perrigo's scale in store-brand OTC products across two continents sets it apart operationally.
What is PRGO's market cap bracket?
Perrigo is classified as a small-cap company. This places it in a segment of the market that can offer valuation opportunities but may also carry higher volatility and less analyst coverage than large- or mega-cap peers.
Who founded Perrigo Company?
Perrigo was founded in 1887, giving it a long operating history in consumer healthcare. Details about the founding individuals are widely available through public historical records and the company's own corporate history materials.
Is PRGO a long-term quality indicator?
From a UQS perspective, PRGO's long-term quality profile is currently rated Below Average, with Weak scores in Quality, Moat, and Growth. Long-term investors should monitor whether the company can improve its competitive positioning and earnings quality before treating it as a durable compounder.
What is the main competitive advantage of Perrigo?
Perrigo's primary competitive position rests on its scale in store-brand OTC manufacturing and its established retail relationships across North America and Europe. However, the UQS Moat pillar rates this advantage as Weak, suggesting the company faces meaningful competitive pressure that limits pricing power and differentiation.
What sector does PRGO belong to?
Perrigo operates in the Healthcare sector, specifically within consumer self-care and OTC health products. It is distinct from pharmaceutical or biotech companies, focusing instead on accessible, non-prescription wellness solutions sold through retail and pharmacy channels.
Is PRGO a growth stock or value stock?
Based on UQS pillar labels, PRGO leans toward the value side — the Valuation pillar is rated Attractive while the Growth pillar is rated Weak. This profile may suit investors seeking discounted entry into a consumer healthcare business rather than those targeting high-growth compounders.
Unlock Full PRGO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores
- ✓Access full financial metrics and trend data
- ✓See how PRGO ranks within the Healthcare sector
- ✓Compare PRGO against peers on every quality dimension
- ✓Get the complete analyst-style breakdown in one view
- ✓Track score changes as new earnings data arrives
Pro Analysis
PRGO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 40.7 | 27.4 | 15.0 | 28.3 | 63.4 | 99.8 | +0.2 |
| May 9, 2026 | 40.5 | 26.8 | 15.0 | 28.3 | 63.4 | 99.5 | -1.2 |
| May 7, 2026 | 41.7 | 29.6 | 15.0 | 28.5 | 66.2 | 99.2 | 0.0 |
| Apr 19, 2026 | 41.8 | 29.6 | 15.0 | 28.7 | 66.2 | 99.5 | 0.0 |
| Apr 14, 2026 | 41.8 | 29.6 | 15.0 | 28.7 | 66.2 | 99.8 | 0.0 |
| Apr 2, 2026 | 41.8 | 29.6 | 15.0 | 28.7 | 66.2 | 99.9 | — |
PRGO — Pillar Breakdown
Quality
— 27.4/100 (25%)Perrigo Company plc currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 28.3/100 (20%)Perrigo Company plc faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 63.4/100 (15%)Perrigo Company plc maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 99.8/100 (15%)Perrigo Company plc appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Moat
— 15/100 (25%)Perrigo Company plc operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PRGO.
Score Composition
Financial Data
More Stock Analysis
How is the PRGO UQS Score Calculated?
The UQS (Unified Quality Score) for Perrigo Company plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Perrigo Company plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Perrigo Company plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.